Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C (IMMHoTHep)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02826447|
Recruitment Status : Unknown
Verified April 2017 by French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS).
Recruitment status was: Recruiting
First Posted : July 11, 2016
Last Update Posted : April 10, 2017
|Condition or disease|
|Exposure to Hepatitis C Virus|
Hepatitis C virus (HCV) is a blood-borne virus and its major route of transmission include blood transfusion, medical injection and procedure, and injecting drug use. In Egypt, the origin of the HCV epidemic has been attributed to a mass treatment of schistosomiasis between 1960 and 1984, when intravenous injections with antimony salts were given to 3-5 million people older than 6 years of age. Insufficient sterilization of needles and syringes was considered to be responsible for HCV transmission at that time. In order to control the spread of HCV in Egypt, the Egyptian Ministry of Health and Population established the National Committee for the Control of Viral Hepatitis. By 2008, this committee developed a National Control Strategy for Viral Hepatitis which has recommended prevention and education campaigns targeting general population and also healthcare workers (HCW). In their occupational environment, HCWs are frequently exposed to multiple blood-borne pathogens, including HCV. Several risk factors for HCV acquisition among patients and HCWs within a hospital ward have been identified, including a high prevalence of HCV infection in the ward, understaffing, workplace characteristic, and human factors such as inexperience or unfamiliar with equipment. However, to the investigators' knowledge, the overall risk of HCV acquisition associated with hospital stay has never been evaluated in Egypt. Also, control measures to reduce the risk of HCV transmission in hospital settings, based on a global assessment of healthcare provider logistics and performance, have never been proposed in Egypt.
In this project, the investigators assume that HCV will be transmitted to both hospital staff and patients. Given the slow dynamics of the HCV epidemic, the investigators further hypothesize that, in the short term, the prevalence of HCV viremia among patients will be constant. Therefore, the investigators are led to conclude that HCV transmission risk may be inferred from a detailed description of individual trajectories of patients or staff within the hospital.
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||550 participants|
|Target Follow-Up Duration:||2 Weeks|
|Official Title:||ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C|
|Actual Study Start Date :||February 21, 2017|
|Estimated Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||April 2018|
500 patients who are going to be hospitalized for at least 24 hours at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
50 healthcare workers working at Ain Shams University Teaching Hospital in the following departments: surgery, internal medicine, gynecology/obstetrics and toxicology.
- Per-day risk of HCV acquisition for a hospitalized patient [ Time Frame: 1 day ]Per-day risk of HCV acquisition for a hospitalized patient
- Per-week risk of HCV acquisition for a healthcare worker through occupational blood exposure [ Time Frame: 1 week ]Per-week risk of HCV acquisition for a healthcare worker through occupational blood exposure
- Estimation of the number of HCV acquisitions among patients and HCWs prevented over a 1-year period following the implementation of various control strategies, using a mathematical modeling approach [ Time Frame: 1 year ]Estimation of the number of HCV acquisitions among patients and HCWs prevented over a 1-year period following the implementation of various control strategies,
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02826447
|Contact: Laura Temime, Professor||+33 1 53 01 80 firstname.lastname@example.org|
|Contact: Wagida Anwar, Professoremail@example.com|
|Ain Shams University Teaching Hospital||Recruiting|
|Contact: Ghada A Ismail, Professor firstname.lastname@example.org|
|Principal Investigator: Wagida Anwar, Professor|
|Sub-Investigator: Ghada A Ismail, Professor|
|Principal Investigator:||Laura Temime, Professor||Conservatoire national des Arts et Métiers|
|Principal Investigator:||Wagida Anwar, Professor||Ain Shams University|